News/Publications
Bendamustine plus rituximab in newly-diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO).
Laribi K, Poulain S, Willems L, Merabet F, Le Calloch R, Eveillard JR, Herbaux C, Roos-Weil D, Chaoui D, Roussel X, Tricot S, Dupuis J, Dartigeas C, Bareau B, Bene MC, Baugier de Materre A, Leblond V.
How I treat rituximab refractory patients with WM.
Gavriatopoulou M, Ntanasis-Stathopoulos I, Kastritis E, Dimopoulos MA.
Clinical Intergroup
Clinical Intergroup
The ECWM is based on a clinical intergroup connecting all major clinical national study groups such as:
- BNLI
- Czech Myeloma Group
- FIL Italian Intergroup
- FCGCLLWM Group
- GLA/OSHO
- Greek Myeloma Study Group
- HOVON
- Nordic Lymphoma Group
- Portuguese Lymphoma Study Group
- Spanish Study Group
The ECWM is associated with the Australasian Leukaemia & Lymphoma Goup (ALLG). This clinical intergroup forms a unique platform for setting up large clinical and innovative trials in a rare disease such as WM.
Currently several clinical trials are initiated which offer patients with WM novel therapeutic approaches in the setting of well controlled clinical trials.